Press Releases

Biocon Biologics  /  Press Releases

Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients

  • Posted by: Biocon Biologics

Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award

  • Posted by: Biocon Biologics

Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®

  • Posted by: Biocon Biologics

Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients

  • Posted by: Biocon Biologics

Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity

  • Posted by: Biocon Biologics

Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr

  • Posted by: Biocon Biologics

Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Recognized among World’s Top 20 Inspirational Leaders in Biopharmaceuticals in The Medicine Maker ‘Power List 2020’

  • Posted by: Biocon Biologics

Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia

  • Posted by: Biocon Biologics
Share
buy twitter followers - omegle - SOL sniper bot - marsbahis güncel giriş